Keros Therapeutics Total Liabilities

Keros Therapeutics (KROS) currently reports a total liabilities of $27M as of March 2026. That compares with $56M in the prior-year period — down 52.1% year over year. Use the charts on this page to explore Keros Therapeutics's total liabilities history and peer comparisons.

Keros Therapeutics's total liabilities decreased from $56M to $27M — a 52.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Keros Therapeutics reported $27M in total liabilities as of March 2026. That compares with $56M in the prior-year period — down 52.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $27M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Keros Therapeutics, and consider following KROS for alerts when major investors trade the stock.

Keros Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $27M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KROS with unrelated industries.